Participated in $65M Series B for Gate Bioscience, advancing oral molecular gate medicines for inflammatory and neurological diseases.
Gate Bioscience is creating a new class of small molecule therapeutics called Molecular Gates, which selectively eliminate harmful extracellular proteins linked to diseases
Gate Bioscience is creating a new class of small molecule therapeutics called Molecular Gates, which selectively eliminate harmful extracellular proteins linked to diseases.